Business News • PR NewsWire • Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes

Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes

Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes

PARIS and THE WOODLANDS, Texas, Nov. 6, 2015 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced today that they have entered into a collaboration and license agreement for the development and commercialization of...

View More : http://www.prnewswire.com/news-releases/sanofi-and-lexicon-pharmaceuticals-to-collaborate-on-sotagliflozin-an-investigat...

Releted News by prnewswire

VimpelCom Reports Net Loss, Good Operational Momentum

Alopecia Therapeutic Pipeline Review for H2 2015 in a Market Research Reports